JP2022544262A5 - - Google Patents

Info

Publication number
JP2022544262A5
JP2022544262A5 JP2022508753A JP2022508753A JP2022544262A5 JP 2022544262 A5 JP2022544262 A5 JP 2022544262A5 JP 2022508753 A JP2022508753 A JP 2022508753A JP 2022508753 A JP2022508753 A JP 2022508753A JP 2022544262 A5 JP2022544262 A5 JP 2022544262A5
Authority
JP
Japan
Prior art keywords
seq
pharmaceutical product
product according
group
palm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022508753A
Other languages
English (en)
Japanese (ja)
Other versions
JP7657775B2 (ja
JP2022544262A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/045785 external-priority patent/WO2021030359A1/en
Publication of JP2022544262A publication Critical patent/JP2022544262A/ja
Publication of JP2022544262A5 publication Critical patent/JP2022544262A5/ja
Application granted granted Critical
Publication of JP7657775B2 publication Critical patent/JP7657775B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022508753A 2019-08-13 2020-08-11 がんの処置に付随する化学療法誘発性末梢神経障害の処置のためのｐａｌｍ Active JP7657775B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962886282P 2019-08-13 2019-08-13
US62/886,282 2019-08-13
PCT/US2020/045785 WO2021030359A1 (en) 2019-08-13 2020-08-11 Palm for the treatment of chemotherapy-induced peripheral neuropathy incidental to the treatment of cancer

Publications (3)

Publication Number Publication Date
JP2022544262A JP2022544262A (ja) 2022-10-17
JP2022544262A5 true JP2022544262A5 (https=) 2023-10-03
JP7657775B2 JP7657775B2 (ja) 2025-04-07

Family

ID=74571179

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022508753A Active JP7657775B2 (ja) 2019-08-13 2020-08-11 がんの処置に付随する化学療法誘発性末梢神経障害の処置のためのｐａｌｍ

Country Status (10)

Country Link
US (1) US20240189230A1 (https=)
EP (1) EP4013444A4 (https=)
JP (1) JP7657775B2 (https=)
KR (1) KR20220045203A (https=)
CN (1) CN114401736A (https=)
AU (1) AU2020329923A1 (https=)
CA (1) CA3147790A1 (https=)
IL (1) IL290487A (https=)
MX (1) MX2022001083A (https=)
WO (1) WO2021030359A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116019911B (zh) * 2022-11-11 2023-11-28 海南大学 一种基于功能化二氧化硅并携载诊疗试剂的纳米颗粒及其制备方法与应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080045559A1 (en) * 2003-10-29 2008-02-21 Sonus Pharmaceuticals, Inc. Tocopherol-modified therapeutic drug compounds
ES2725023T3 (es) * 2006-10-12 2019-09-18 Galera Labs Llc Métodos para el tratamiento de la mucositis oral
US9233163B2 (en) * 2010-12-28 2016-01-12 The Children's Hospital Of Philadelphia Hydrolytically releasable prodrugs for sustained release nanoparticle formulations
SG2014014294A (en) * 2011-04-11 2014-06-27 Abbvie Inc Parp inhibitors for the treatment of cipn
EP2861256B1 (en) * 2012-06-15 2019-10-23 The Brigham and Women's Hospital, Inc. Compositions for treating cancer and methods for making the same
EP3096755A4 (en) * 2014-01-23 2017-12-27 Sova Pharmaceuticals, Inc. CYSTATHIONINE-(gamma)-LYASE (CSE) INHIBITORS FOR TREATING PAIN
BR112016022499A2 (pt) * 2014-04-03 2017-08-15 Invictus Oncology Pvt Ltd Produtos terapêuticos combinatórios supramoleculares
JP2018528257A (ja) * 2015-07-10 2018-09-27 ペプティノボ・バイオファーマ・リミテッド・ライアビリティ・カンパニーＰｅｐｔｉｎｏｖｏ Ｂｉｏｐｈａｒｍａ， ＬＬＣ 疎水性薬剤の効能を改善するための配合物
BR112018000217A2 (pt) * 2015-07-15 2018-09-04 Celator Pharmaceuticals Inc sistemas de distribuição de nanopartículas aperfeiçoados
EP3439666A4 (en) * 2016-05-20 2019-12-11 The University of Chicago NANOPARTICLES FOR CHEMOTHERAPY, TARGETED THERAPY, PHOTODYNAMIC THERAPY, IMMUNOTHERAPY AND ALL COMBINATIONS THEREOF

Similar Documents

Publication Publication Date Title
Li et al. Targeting tumor highly-expressed LAT1 transporter with amino acid-modified nanoparticles: toward a novel active targeting strategy in breast cancer therapy
Suga et al. Ligand peptide-grafted PEGylated liposomes using HER2 targeted peptide-lipid derivatives for targeted delivery in breast cancer cells: the effect of serine-glycine repeated peptides as a spacer
JP3415131B1 (ja) リポソーム製剤
Shmeeda et al. Her2-targeted pegylated liposomal doxorubicin: retention of target-specific binding and cytotoxicity after in vivo passage
EP2450031B1 (en) Method for producing liposomes by two-stage emulsification method using outer aqueous phase containing specific dispersing agent, method for producing liposome dispersion or dry powder thereof using the method for producing liposomes, and liposome dispersion or dry powder thereof produced thereby
EP3372232B1 (en) Tumor therapeutic agent comprising gemcitabine liposome composition and kit
He et al. Recent development of poly (ethylene glycol)-cholesterol conjugates as drug delivery systems
WO2012031175A4 (en) Nanoparticle-based tumor-targeted drug delivery
JP2022541740A5 (https=)
US20180110831A1 (en) Cd 47 containing porous nanoparticle supported lipid bilayers (protocells) field of the invention
EP1863448A2 (en) Novel liposome compositions
US12370214B2 (en) Combined pharmaceutical formulation comprising drug-containing liposome composition and platinum preparation
EP2215107A1 (en) Peptide ligand directed drug delivery
Kato et al. Synthesis and evaluation of a novel adapter lipid derivative for preparation of cyclic peptide-modified PEGylated liposomes: Application of cyclic RGD peptide
WO2008030818A2 (en) Novel liposome compositions
US20230265123A1 (en) Peptides and formulations for cancer treatment
US12370186B2 (en) Combined pharmaceutical formulation comprising drug-containing liposome composition and immune checkpoint inhibitor
JP2022544262A5 (https=)
JP2018528257A5 (https=)
CN106831997B (zh) 多肽、脂蛋白样纳米粒子及其应用
CN108350036B (zh) 用于改善疏水性药物功效的制剂
Han et al. Therapeutic approaches of dual-targeted nanomedicines for tumor multidrug resistance
EP3202424A1 (en) Kit for formulation of liposomal doxorubicin modified with bioactive peptides for selective targeting of receptors overexpressed by cancer cells
Deng et al. Developing a novel P-glycoprotein inhibitor and pairing it with oral paclitaxel liposomes for enhanced cancer therapy
EP4368657A1 (en) Ph-responsive lipid derivative